Pharmaceutical Technology41m
QL-401 by QLSF Biotherapeutics for Relapsed Acute Myeloid Leukemia: Likelihood of Approval
QL-401 is under clinical development by QLSF Biotherapeutics and currently in Phase I for Relapsed Acute Myeloid Leukemia.
Pharmaceutical Technology41m
Vebeglogene autotemcel by Lantu Biopharma for Beta Thalassaemia: Likelihood of Approval
Vebeglogene autotemcel is under clinical development by Lantu Biopharma and currently in Phase II for Beta Thalassaemia.
Pharmaceutical Technology41m
QL-401 by QLSF Biotherapeutics for Refractory Acute Myeloid Leukemia: Likelihood of Approval
QL-401 is under clinical development by QLSF Biotherapeutics and currently in Phase I for Refractory Acute Myeloid Leukemia.
Pharmaceutical Technology41m
XB-010 by Exelixis for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval
XB-010 is under clinical development by Exelixis and currently in Phase I for Triple-Negative Breast Cancer (TNBC).
Pharmaceutical Technology43m
CLN-619 by Cullinan Therapeutics for Refractory Multiple Myeloma: Likelihood of Approval
CLN-619 is under clinical development by Cullinan Therapeutics and currently in Phase I for Refractory Multiple Myeloma.
Pharmaceutical Technology41m
20ND02 by HK inno.N for Glaucoma: Likelihood of Approval
ND02 is under clinical development by HK inno.N and currently in Phase II for Glaucoma. According to GlobalData, Phase II drugs for Glaucoma have a 39% phase transition success rate (PTSR) indication ...
Pharmaceutical Technology7h
SMART-101 by Smart Immune for Refractory Acute Myeloid Leukemia: Likelihood of Approval
SMART-101 is under clinical development by Smart Immune and currently in Phase II for Refractory Acute Myeloid Leukemia.
Pharmaceutical Technology7h
EBBH-2024 by Essen Biotech for Diffuse Large B-Cell Lymphoma: Likelihood of Approval
EBBH-2024 is under clinical development by Essen Biotech and currently in Phase II for Diffuse Large B-Cell Lymphoma.
Pharmaceutical Technology7h
AKS-452 by Vakston for Coronavirus Disease 2019 (COVID-19): Likelihood of Approval
AKS-452 is under clinical development by Vakston and currently in Phase II for Coronavirus Disease 2019 (COVID-19).
Pharmaceutical Technology7h
SY-001 by CellOrigin Technology (Hangzhou) for Pancreatic Cancer: Likelihood of Approval
SY-001 is under clinical development by CellOrigin Technology (Hangzhou) and currently in Phase I for Pancreatic Cancer.
Pharmaceutical Technology7h
LY-4052031 by Eli Lilly and Co for Ovarian Cancer: Likelihood of Approval
LY-4052031 is under clinical development by Eli Lilly and Co and currently in Phase I for Ovarian Cancer. According to GlobalData, Phase I drugs for Ovarian Cancer have a 73% phase transition success ...